137 related articles for article (PubMed ID: 9640842)
1. Cancer cell cycle and adoptive immunotherapy using lymphokine-activated killer cells.
Ejiri Y; Ohara M; Suzuki T; Kasukawa R
Fukushima J Med Sci; 1997 Dec; 43(2):61-73. PubMed ID: 9640842
[TBL] [Abstract][Full Text] [Related]
2. Cell cycle assessment of adoptive transferred lymphokine activated killer cells.
Watanabe R; Tanaka N; Naomoto Y; Moreira LF; Orita K
Jpn J Clin Oncol; 1994 Apr; 24(2):59-65. PubMed ID: 8158860
[TBL] [Abstract][Full Text] [Related]
3. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of lymphokine-activated killer cell cytotoxicity implicated in the increased expression of surface adhesion molecules on tumor cells treated with anticancer agents.
Ishihata R; Ejiri Y; Okubo M; Ohara M; Kasukawa R
Cancer Invest; 1996; 14(5):427-34. PubMed ID: 8816858
[TBL] [Abstract][Full Text] [Related]
5. [LAK sensitivity of human pancreas carcinoma cell lines].
Sugiura H
Hokkaido Igaku Zasshi; 1993 Nov; 68(6):921-34. PubMed ID: 7906667
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells.
Yamaue H; Tanimura H; Noguchi K; Iwahashi M; Tsunoda T; Tani M; Tamai M; Hotta T; Mizobata S; Arii K
J Clin Lab Immunol; 1991 Aug; 35(4):165-70. PubMed ID: 1668852
[TBL] [Abstract][Full Text] [Related]
7. Tretinoin or retinol enhancement of lymphokine-activated killer cell proliferation and cytotoxicity against human bladder cancer cells in vitro.
Wang ZP; Zheng RL; Chen YR; Liu GD
Zhongguo Yao Li Xue Bao; 1997 Nov; 18(6):522-4. PubMed ID: 10322910
[TBL] [Abstract][Full Text] [Related]
8. Different susceptibility of cervical keratinocytes containing human papillomavirus to cell-mediated cytotoxicity.
Wu R; Coleman N; Stanley M
Chin Med J (Engl); 1996 Nov; 109(11):854-8. PubMed ID: 9275369
[TBL] [Abstract][Full Text] [Related]
9. Reduction of LAK-sensitivity and changes in antigen expression on hepatoma cells by sodium butyrate.
Tada S; Saito H; Ebinuma H; Atsukawa K; Masuda T; Tsunematsu S; Morizane T; Ishii H
Cancer Biochem Biophys; 1996 Apr; 15(3):177-86. PubMed ID: 8937741
[TBL] [Abstract][Full Text] [Related]
10. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
Provinciali M; Di Stefano G; Stronati S; Fabris N
Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
[TBL] [Abstract][Full Text] [Related]
11. The role of N-linked carbohydrate residues in lymphokine-activated killer cell-mediated cytolysis.
Mehta BA; Collard HR; Negrin RS
Cell Immunol; 1994 Apr; 155(1):95-110. PubMed ID: 7909499
[TBL] [Abstract][Full Text] [Related]
12. All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity.
Chao TY; Jiang SY; Shyu RY; Yeh MY; Chu TM
Br J Cancer; 1997; 75(9):1284-90. PubMed ID: 9155047
[TBL] [Abstract][Full Text] [Related]
13. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface.
Komatsu F; Kajiwara M
Oncol Res; 1998; 10(5):263-9. PubMed ID: 9802061
[TBL] [Abstract][Full Text] [Related]
14. [Cytotoxicity of human lymphokine-activated killer cells against mitotic phase tumor cells].
Liu GR
Zhonghua Yi Xue Za Zhi; 1993 Sep; 73(9):547-8, 576. PubMed ID: 8313200
[TBL] [Abstract][Full Text] [Related]
15. [Cytotoxicities of low dose anticancer agents combining lymphokine activated killer cell against ovarian adenocarcinoma cell line SKOV3].
Chen R; Pan L; Zhou S
Zhonghua Fu Chan Ke Za Zhi; 1999 Mar; 34(3):172-4. PubMed ID: 11263191
[TBL] [Abstract][Full Text] [Related]
16. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
[TBL] [Abstract][Full Text] [Related]
17. [Apoptosis of tumor cells in lectin-dependent lymphokine-activated killer cell-mediated cytotoxicity].
Dong H; Xing R; Guo L
Zhonghua Zhong Liu Za Zhi; 1995 Jul; 17(4):245-8. PubMed ID: 7587887
[TBL] [Abstract][Full Text] [Related]
18. DNA-protein cell content of lymphokine activated killer (LAK) and target cells in coculture.
Nano R; Barni S; Capelli E; Prosperi E; Lavezzi L; Salvucci O
Anticancer Res; 1995; 15(3):751-4. PubMed ID: 7645953
[TBL] [Abstract][Full Text] [Related]
19. Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells.
Iwahashi M; Tanimura H; Yamaue H; Tani M; Noguchi K; Mizobata S; Tsunoda T; Tamai M; Hotta T; Arii K
Anticancer Res; 1994; 14(4A):1563-8. PubMed ID: 7979186
[TBL] [Abstract][Full Text] [Related]
20. Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation, or splenectomy.
Kawata A; Hosokawa M; Sawamura Y; Ito K; Une Y; Shibata T; Uchino J; Kobayashi H
Mol Biother; 1990 Dec; 2(4):221-7. PubMed ID: 2288722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
